# UNITING DOCTORS - AATD AWARENESS CAMPAIGN

**Last Updated**: November 8, 2025

---

## üéØ Mission: Raising AATD Awareness

Alpha-1 Antitrypsin Deficiency (AATD) is a genetic condition affecting an estimated 100,000+ Americans, yet it remains severely under-diagnosed. Our platform's origin story centers on AATD awareness, making this a core pillar of Uniting Doctors.

---

## üìä AATD Background

### What is AATD?

**Alpha-1 Antitrypsin Deficiency** is a genetic disorder that primarily affects the lungs and liver:
- **Genetic**: Inherited from both parents (autosomal recessive)
- **Protein Deficiency**: Low levels of alpha-1 antitrypsin (AAT) protein
- **Organ Damage**: AAT protects lungs from neutrophil elastase damage
- **Symptoms**: COPD-like symptoms, often misdiagnosed as asthma or COPD

### The Under-Diagnosis Problem

**Current State**:
- Estimated 100,000-200,000 affected individuals in the US
- Only ~10,000 diagnosed (95% undiagnosed)
- Average 5-7 years from symptom onset to diagnosis
- Often misdiagnosed as asthma, COPD, or chronic bronchitis

**Why Under-Diagnosed**:
- ‚ùå Low awareness among physicians (not taught in medical school)
- ‚ùå Symptoms overlap with common conditions
- ‚ùå Simple test exists but rarely ordered
- ‚ùå No standardized screening protocols

---

## üéØ Campaign Goals

### Primary Goals
1. **Educate 100,000+ medical professionals** about AATD in Year 1
2. **Increase AATD testing rates** by 25% in target specialties
3. **Reduce time to diagnosis** from 5-7 years to <2 years
4. **Build AATD community** of specialists, patients, and advocates

### Secondary Goals
1. Advocate for AATD screening in at-risk populations
2. Connect diagnosed patients with specialists
3. Share latest AATD research and treatment options
4. Support AATD families and caregivers

---

## üìö Educational Content Strategy

### Launch Content (Month 1)

#### "AATD 101" Educational Series
1. **Post 1**: "What Every Physician Should Know About AATD"
   - Quick facts, symptoms, testing
   - Infographic: AATD at a glance
   - CTA: Order simple blood test

2. **Post 2**: "The Cost of Missed AATD Diagnoses"
   - Case studies of late diagnoses
   - Impact on patients and families
   - Preventable complications

3. **Post 3**: "AATD Testing: A Simple Blood Test Can Save Lives"
   - Who to test (screening guidelines)
   - How to order test (lab codes)
   - Insurance coverage information

4. **Post 4**: "MZ Genotype: An Underestimated Risk"
   - MZ carriers and COPD risk
   - Recent research updates
   - Clinical implications

5. **Post 5**: "AATD Treatment Options in 2025"
   - Augmentation therapy
   - Lifestyle modifications
   - Clinical trials and research

#### Weekly AATD Content
- **Monday**: AATD fact of the week
- **Wednesday**: Case study or patient story
- **Friday**: Latest research or clinical update

---

### Content Types

#### 1. Educational Posts
- Quick facts and statistics
- Symptom checklists
- Diagnostic algorithms
- Treatment guidelines
- Infographics and visuals

#### 2. Case Studies (Anonymized)
- Late diagnosis stories
- Successful early intervention
- Atypical presentations
- Family screening examples

#### 3. Research Updates
- Latest PubMed publications
- Clinical trial results
- Treatment breakthroughs
- Genetic research

#### 4. Expert AMAs (Ask Me Anything)
- Pulmonologists specializing in AATD
- Genetic counselors
- AATD patients and advocates
- Researchers

#### 5. Interactive Content
- Polls: "Have you ever ordered an AAT level test?"
- Quizzes: "AATD Knowledge Check"
- Discussion prompts: "Share your AATD diagnosis story"

---

## üë• Target Audiences

### Primary Audience: Pulmonologists
**Why**: AATD primarily affects lungs; pulmonologists are first-line
**Tactics**:
- Partner with American Thoracic Society
- Present at pulmonology conferences
- Targeted LinkedIn/X outreach
- CME credits for AATD education

### Secondary Audiences

#### 1. Primary Care Physicians / GPs
**Why**: First point of contact for symptomatic patients
**Tactics**:
- Simple screening guidelines
- "When to suspect AATD" checklist
- Referral pathways to specialists

#### 2. Hepatologists
**Why**: AATD can cause liver disease
**Tactics**:
- Liver-focused AATD content
- Partner with liver disease organizations

#### 3. Pediatricians
**Why**: Childhood liver disease, family screening
**Tactics**:
- Pediatric AATD presentations
- Family screening protocols

#### 4. Allergists / Immunologists
**Why**: Patients often misdiagnosed with asthma
**Tactics**:
- Differential diagnosis education
- "Not all wheezing is asthma" content

---

## ü§ù Partner Organizations

### Mark Egly Foundation
**Role**: Primary sponsor and content partner
**Contribution**:
- AATD educational materials
- Patient stories and testimonials
- Specialist network
- Funding support

### Alpha-1 Foundation
**Role**: National AATD advocacy organization
**Collaboration**:
- Co-branded awareness campaigns
- Access to physician network
- Research updates
- Patient resources

### American Thoracic Society (ATS)
**Role**: Professional medical society
**Collaboration**:
- Conference presentations
- CME accreditation
- Clinical guideline dissemination

---

## üìÖ Campaign Timeline

### Pre-Launch (Month -1)
- Develop AATD content library
- Record expert videos
- Design infographics
- Recruit AATD specialists to platform

### Launch (Month 1)
- Launch AATD awareness week
- Daily AATD posts
- Expert AMA sessions
- Press release: "New Platform Tackles AATD Under-Diagnosis"

### Months 2-6
- Weekly AATD content
- Monthly expert Q&A
- Case study series
- Research roundup

### Year 1 Milestone: AATD Awareness Month (May)
- Special focus on AATD throughout May
- Virtual conference on AATD
- Patient and physician panels
- Media outreach

---

## üìä Success Metrics

### Awareness Metrics
- Medical professionals educated: 100,000+
- AATD content views: 1M+
- AATD group members: 5,000+
- Expert contributors: 50+

### Clinical Impact (Long-term)
- Increased AATD testing rates (track via surveys)
- Reduced time to diagnosis (patient surveys)
- More AATD diagnoses made via platform connections

### Engagement Metrics
- AATD post engagement rate: >10%
- Expert AMA attendance: 500+ per session
- Content saves/shares: 10,000+

---

## üåü Unique Features for AATD

### AATD-Specific Group
**Features**:
- Dedicated "AATD & Rare Lung Diseases" group
- Specialist directory (find AATD experts)
- Patient resource library
- Clinical trial tracker
- Family screening guidance

### AATD Research Feed
**Features**:
- Auto-aggregated AATD research from PubMed
- Weekly research digest
- Specialist commentary on studies
- Clinical application discussions

### AATD Testing Tool
**Features**:
- "Should I Test My Patient?" decision tool
- Lab ordering information
- Insurance pre-authorization guidance
- Patient education handouts

---

## üí° Campaign Innovations

### 1. AATD Specialist Network
Build directory of AATD specialists willing to:
- Consult on complex cases
- Accept referrals
- Mentor physicians
- Contribute educational content

### 2. Virtual AATD Clinic Rounds
Monthly virtual case discussions:
- Challenging AATD cases
- Treatment decision-making
- Multidisciplinary approach
- CME credits available

### 3. AATD Diagnostic Challenge
Gamified learning:
- Present clinical scenarios
- Physicians suggest diagnoses
- Reveal AATD as underlying cause
- Educational follow-up content

---

## üó£Ô∏è Key Messages

### For Physicians
- "A simple blood test can change a patient's life"
- "AATD is more common than you think‚Äîand more treatable"
- "Don't miss AATD: Know the signs, order the test"
- "Early diagnosis prevents decades of mismanagement"

### For Patients (via Physicians)
- "If you have COPD symptoms, ask about AATD testing"
- "Family history matters: Screen your relatives"
- "AATD is treatable when caught early"
- "You are not alone: Join our community"

---

## üì± AATD Content Calendar (Month 1)

**Week 1: Introduction**
- Day 1: AATD overview infographic
- Day 2: Why physicians miss AATD
- Day 3: Case study: Late diagnosis
- Day 4: Testing guidelines
- Day 5: Expert AMA announcement

**Week 2: Diagnosis**
- Day 1: Symptoms checklist
- Day 2: Differential diagnosis
- Day 3: Lab testing deep dive
- Day 4: Genetic counseling
- Day 5: Expert AMA with pulmonologist

**Week 3: Treatment**
- Day 1: Augmentation therapy explained
- Day 2: Lifestyle modifications
- Day 3: Monitoring and follow-up
- Day 4: Clinical trials
- Day 5: Patient success story

**Week 4: Family & Community**
- Day 1: Family screening importance
- Day 2: Genetic inheritance patterns
- Day 3: Support resources
- Day 4: Mark Egly Foundation spotlight
- Day 5: Community call-to-action

---

## üé§ Spokespersons & Advocates

### Medical Experts
- Pulmonologists specializing in AATD
- Genetic counselors
- Hepatologists (for liver manifestations)

### Patient Advocates
- Mark Egly Foundation representatives
- AATD patients willing to share stories
- Family members and caregivers

### Researchers
- Scientists studying AATD genetics
- Clinical trial investigators
- Treatment development researchers

---

## üèÜ Long-Term Vision

**5-Year Goal**: Make AATD a household term in the medical community

**10-Year Goal**: Reduce undiagnosed AATD rate from 95% to <50%

**Ultimate Goal**: Every physician knows to test for AATD, every patient gets diagnosed early, every family gets screened

---

**Next Steps**:
1. Finalize AATD content library
2. Recruit AATD specialists to platform
3. Partner with Alpha-1 Foundation
4. Launch AATD awareness week
5. Track impact and iterate
